BioCryst Q3 revenue rises 13% on ORLADEYO sales
BCRX•BCRX•BCRX•BCRX•BioCryst’s third-quarter revenue rose 13% year over year, driven by ORLADEYO sales and the CareMed transition. The company reported net income of $37.92 million and raised 2026 total revenue guidance to $715 million-$730 million while maintaining ORLADEYO guidance of $625 million-$645 million.
BioCryst said third-quarter revenue increased 13% year over year, driven by ORLADEYO sales and its transition to CareMed as its sole-source specialty pharmacy partner. The company reported net income of $37.92 million and earnings per share of $0.14.
BioCryst maintained its 2026 ORLADEYO revenue guidance of $625 million to $645 million and raised total revenue guidance to $715 million-$730 million. It lowered its 2026 non-GAAP operating expense guidance to $415 million-$425 million.
The company said CareMed built initial ORLADEYO inventory to support patient demand. The launch of ORLADEYO oral pellets for pediatric patients began in August, with early reimbursement described as strong and new prescriptions ahead of expectations.
